Wagner, V., Hose, D., Seckinger, A., Weiz, L., Meißner, T., Breitkreutz, I., . . . Raab, M. (2014). Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. OncoTarget, 5(21), . https://doi.org/10.18632/oncotarget.2529
Chicago-Zitierstil (17. Ausg.)Wagner, Verena, et al. "Preclinical Efficacy of Sepantronium Bromide (YM155) in Multiple Myeloma Is Conferred by Down Regulation of Mcl-1." OncoTarget 5, no. 21 (2014). https://doi.org/10.18632/oncotarget.2529.
MLA-Zitierstil (9. Ausg.)Wagner, Verena, et al. "Preclinical Efficacy of Sepantronium Bromide (YM155) in Multiple Myeloma Is Conferred by Down Regulation of Mcl-1." OncoTarget, vol. 5, no. 21, 2014, https://doi.org/10.18632/oncotarget.2529.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.